| Company Name: |
EMMX Biotechnology LLC
|
| Tel: |
888-539-0666 |
| Email: |
info@emmx.com |
| Products Intro: |
Product Name:GGTI 297
CAS:181045-83-0
Purity:98% HPLC Package:5mg;10mg;25mg;50mg;100mg;250mg;500mg;1g
|
| Company Name: |
Nantong Hi-Future Biotechnology Co., Ltd
|
| Tel: |
18051384581 |
| Email: |
sales@chemhifuture.com |
| Products Intro: |
Product Name:GGTI-297
CAS:181045-83-0
Purity:98%+ HPLC Package:10mg，100mg，500mg，1g，2g，5g，10g，more
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:GGTI-297
CAS:181045-83-0
Package:50mg/RMB 16800;25mg/RMB 12800;100mg/RMB 21500
|
GGTI-297 manufacturers
- GGTI-297
-
- $2380.00 / 50mg
-
2025-07-16
- CAS:181045-83-0
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | GGTI-297 Basic information |
| Product Name: | GGTI-297 | | Synonyms: | GGTI-297;N-4-[2(R)-AMINO-3-MERCAPTOPROPYL]AMINO-2-NAPHTHYLBENZOYL-(L)-LEUCINE, TFA;L-Leucine, N-[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)benzoyl]- | | CAS: | 181045-83-0 | | MF: | C26H31N3O3S | | MW: | 465.61 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | GGTI-297 Chemical Properties |
| Boiling point | 709.0±60.0 °C(Predicted) | | density | 1.232±0.06 g/cm3(Predicted) | | pka | 3.70±0.10(Predicted) |
| | GGTI-297 Usage And Synthesis |
| Description | GGTI-297 is a potent, cell-permeable, and selective peptidomimetic inhibitor of GGTase I compared to Farnesyl Transferase (FTase). | | Uses | GGTI-297 is a geranylgeranyl transferase I (GGTase-1) inhibitor with IC50 values of 56 nM and 203 nM for GGTase-1 and fanesyl transferase (FTase), respectively. GGTI-297 inhibits the processing of the geranylgeranylated protein Rap1A without affecting the farnesylated protein H-Ras[1][2]. | | Definition | ChEBI: (2S)-2-[[[4-[[(2R)-2-amino-3-mercaptopropyl]amino]-2-(1-naphthalenyl)phenyl]-oxomethyl]amino]-4-methylpentanoic acid is a leucine derivative. | | in vivo | GGTI-297 (70 mg/kg; ip; once a day; for 5-7 weeks) inhibits the growth in nude mice of A-549 and Calu-1 xenografts, both of which express K-Ras mutations[2].
| Animal Model: | Nude mice injected (8 week old) with A-549 or Calu-1 cells[2] | | Dosage: | 70 mg/kg | | Administration: | ip; once a day; for 5 weeks (A-549 cells) and 12 weeks (Calu-1) | | Result: | Inhibited the growth in nude mice of A-549 and Calu-1 xenografts.
|
| | References | [1] Y Qian, et al. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. Bioorg Med Chem. 1998 Mar;6(3):293-9. DOI:10.1016/s0968-0896(97)10040-2
[2] J Sun, et al. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene. 1998 Mar;16(11):1467-73. DOI:10.1038/sj.onc.1201656 |
| | GGTI-297 Preparation Products And Raw materials |
|